CRVS CIK: 1626971

Corvus Pharmaceuticals, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−36.7
FY22:
−27.0
FY23:
−23.9
FY24:
−25.4
FY25:
−32.8
Change from FY21 to FY25
millions USD
FY21:
21.6
FY22:
−23.3
FY23:
15.5
FY24:
−27.5
FY25:
−7.80
Change from FY21 to FY25
millions USD
FY21:
62.2
FY22:
0
FY23:
7.86
FY24:
49.0
FY25:
36.4
millions USD
FY21:
47.0
FY22:
−50.3
FY23:
−0.54
FY24:
−3.88
FY25:
−4.16
(positive)
Change from FY21 to FY25
millions USD
FY21:
−36.7
FY22:
−27.3
FY23:
−24.0
FY24:
–
FY25:
−33.0

All amounts in millions USD Data source:SEC EDGAR